Novonesis signs deal to buy remaining stake in MicroBioGen
Reuters2026/08/10 07:05- Novozymes will acquire the remaining shares of MicroBioGen, lifting its stake from 23% to full ownership.
- MicroBioGen is an Australian biotech focused on yeast strains for industrial use, with a core position in bioethanol.
- The deal extends a partnership dating to Novozymes’ 2013 investment, aimed at strengthening yeast and R&D capabilities.
- Financial terms were not disclosed; closing is subject to customary regulatory clearances, including review by Australia’s ACCC.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Expensive Protection" Arbitrage Opportunities in a Calm US Stock Market: SocGen Recommends Selling Short-Term Tail Volatility, but Hedging Against Crash Risks
Société Générale stated that the surge in short-term S&P 500 option premiums is creating attractive opportunities for selling volatility strategies, but it is necessary to hedge against downside risk.
BUUU Group signs deal to buy 60% stake in modular data center provider Brightray Science
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Crypto prices
More
